Oncology Pharma Inc.
ONPH · OTC
12/31/2022 | 9/30/2022 | 6/30/2022 | 12/31/2004 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.13 | -0.00 | 0.00 | -0.04 |
| FCF Yield | -0.02% | -0.02% | 0.03% | -1.62% |
| EV / EBITDA | -2,168.21 | -206.96 | -4,894.97 | -64.78 |
| Quality | ||||
| ROIC | -0.34% | -4.40% | -0.54% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.01 | 0.00 | -0.73 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -69.12% |
| Free Cash Flow Growth | 44.89% | -120.91% | 0.00% | -8,000.00% |
| Safety | ||||
| Net Debt / EBITDA | -121.82 | -9.24 | -66.97 | -3.05 |
| Interest Coverage | -0.03 | -0.02 | -0.78 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |